EP1264178A2 - Anordnung und verfahren zur untersuchung von wirkstoffen zur beeinflussung intrazellulärer vorgänge - Google Patents
Anordnung und verfahren zur untersuchung von wirkstoffen zur beeinflussung intrazellulärer vorgängeInfo
- Publication number
- EP1264178A2 EP1264178A2 EP01925461A EP01925461A EP1264178A2 EP 1264178 A2 EP1264178 A2 EP 1264178A2 EP 01925461 A EP01925461 A EP 01925461A EP 01925461 A EP01925461 A EP 01925461A EP 1264178 A2 EP1264178 A2 EP 1264178A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- fcs
- fluorescence
- measurement
- addition
- dimers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000004480 active ingredient Substances 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title claims abstract description 20
- 230000006525 intracellular process Effects 0.000 title claims abstract description 5
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 27
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 27
- 238000005259 measurement Methods 0.000 claims abstract description 22
- 239000000539 dimer Substances 0.000 claims abstract description 20
- 239000000178 monomer Substances 0.000 claims abstract 5
- 102000004243 Tubulin Human genes 0.000 claims description 17
- 108090000704 Tubulin Proteins 0.000 claims description 17
- 239000013543 active substance Substances 0.000 claims description 16
- 238000009792 diffusion process Methods 0.000 claims description 11
- 102000007469 Actins Human genes 0.000 claims description 6
- 108010085238 Actins Proteins 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 230000036962 time dependent Effects 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 5
- 102000013498 tau Proteins Human genes 0.000 claims description 5
- 108010026424 tau Proteins Proteins 0.000 claims description 5
- 238000011835 investigation Methods 0.000 claims description 3
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 claims description 2
- 229950006344 nocodazole Drugs 0.000 claims description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims 2
- 229960001338 colchicine Drugs 0.000 claims 1
- -1 vinoblastin Chemical compound 0.000 claims 1
- 102000029749 Microtubule Human genes 0.000 description 11
- 108091022875 Microtubule Proteins 0.000 description 11
- 210000004688 microtubule Anatomy 0.000 description 11
- 238000002060 fluorescence correlation spectroscopy Methods 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- 239000000872 buffer Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 102000007474 Multiprotein Complexes Human genes 0.000 description 4
- 108010085220 Multiprotein Complexes Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 229960003048 vinblastine Drugs 0.000 description 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 1
- 101710115937 Microtubule-associated protein tau Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- 230000003327 cancerostatic effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6408—Fluorescence; Phosphorescence with measurement of decay time, time resolved fluorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
Definitions
- active substances such as paciitaxel or vinblastine can be detected, which limit the viability of cells by disturbing the assembly balance or the assembly dynamics of proteins and protein complexes.
- the method is therefore suitable for contributing to the development of cancerostatics and cytocids (fungicides, herbicides, etc.).
- FCS fluorescence correlation spectroscopy
- the binding of both proteins is detected by the simultaneous detection of both fluorescent labels in the focused volume of the microscope.
- the detection of the binding takes place via the difference in the diffusion rate between the fluorescence-labeled protein which is not bound to the significantly larger partner protein, which has a high diffusion rate, or the fluorescence-labeled protein which is bound to the significantly larger partner protein, which is a significantly lower rate and thus has a distinguishable diffusion rate.
- the FCS is . a modern measuring method. Fluorescence events originating from individual molecules are registered and statistically evaluated using a correlation analysis. From these ensemble statistics one can determine the diffusion speed, which allows conclusions to be drawn about the size and the binding behavior of molecular-biological reactions.
- the FCS works via confocal imaging with a cw laser excitation. Individual molecules diffuse through the defined detection volume (femtoliter) and a photon shower is emitted by the fluorescence label, which is registered by an Avelange diode. The photon showers can only be differentiated if the concentration of the fluorescent molecules is less than 10 "8 M, which means that this method can be used to study such small amounts of molecules down to the picomole range.
- Assemblable proteins such as. B. tubulin, actin, tau protein, are an indispensable part of the cells. Balances of these proteins between their monomeric, oligomeric and polymeric form are a necessary prerequisite for life.
- the invention is based on influencing exchange kinetics irrf assembly equilibrium of proteins and protein complexes, the disruption of these exchange kinetics z. B. by active ingredients and the detection of these disorders. This makes it possible to detect the effects of active substances in concentration ranges close to the pharmacologically achievable conditions.
- the special progress of this method lies in the focus on minimal changes in equilibrium due to the lowest active substance concentrations instead of the otherwise usual influencing of the assembly of proteins and protein complexes by means of pharmacologically unreachable high active substance concentrations.
- This invention attains particular value by overcoming the problem of having to use rapid assays with drug concentrations that are too high or pharmacologically relevant drug concentrations in complex and expensive assays that are not suitable for high throughput screening (HTS).
- This test can be carried out in microtiter format and is therefore suitable for HTS in large substance libraries.
- the installation depends on the equilibrium and the exchange kinetics between polymer (microtubule) and dimer.
- the assembly is, for example, in a buffer of the composition:
- Tubuiindimeren now becomes a small amount of 10 "9 M rhodamine-labeled tubulin
- FCS Fluorescence correlation measurement
- a temperature control plate is advantageously provided under the sample vessel, which has a recess for the optical path of the
- Microscope has.
- Figure 1a shows the decrease in the proportion of "faster” dimers based on the decrease in diffusion time
- Figure 1b shows the increase in "slow” polymers until equilibrium is reached
- Active ingredients such as paciitaxel or vinblastine, both used against human cancers, are able to hinder this exchange between tubulin dimer and polymer in substoichiometric proportions.
- the pharmacologically relevant potential of the above-mentioned active ingredients is therefore not to prevent or shift the equilibrium between the protein polymer and dimer at clearly substoichiometric concentrations, but rather to hinder the dynamic exchange in equilibrium in whole or in part.
- this property of the microtubules as well as other assemblable proteins is a prerequisite for the cells to live. Cancer cells with their increased metabolism require the flexibility of the microtubules • more than somatic cells, which is one reason for the relatively selective action of the above-mentioned active substances against cancer cells.
- the active ingredient can be added here in pharmacologically relevant concentrations.
- the effect of substances with a known effect on the kinetics described can be followed up to concentrations of 10 "11 M.
- a small amount of, for example, 10 "9 M rhodamine-labeled tubulin (or another fluorescence-labeled tubulin) in the tubulin assembly buffer described above is now dissolved in this solution of the adjusted equilibrium between microtubules and tubuiindimers.
- An FCS measurement is again carried out in a microtiter plate At the beginning of the measurement, only fluorescence-labeled tubulin dimers with a fast diffusion constant are present in the solution and can be detected on the basis of the diffusion time.
- a temperature control plate can be provided under the X / Y table, which maintains the set temperature of the assembly equilibrium and one
- sample vessels can be combined in a microtiter plate (MTP), the pipetting and subsequent measurement in an opening of the MTP without
- Active ingredients can be added and in further openings the measurement with added active ingredient.
- Throw averaged and at least one second value is determined in at least one second scanning step and a time course is determined in this way.
- the measured value or measured value course of the measurement without active ingredient is stored and in each case with measured values or value courses with the addition of
- Actin is generally stored at -80 ° C
- Buffer to a concentration of 1 mg / ml and let stand for at least 1 hour.
- tau protein is stored at -80 ° C. Then thawed at 4 ° C, diluted with 10mM Tris pH 7.2, containing DTT or ß-mercaptoethanol and at
- ATP adenosine triphosphate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10013854 | 2000-03-17 | ||
DE10013854A DE10013854A1 (de) | 2000-03-17 | 2000-03-17 | Anordnung und Verfahren zur Untersuchung von Wirkstoffen zur Beeinflussung intrazellulärer Vorgänge |
PCT/EP2001/002922 WO2001068680A2 (de) | 2000-03-17 | 2001-03-15 | Anordnung und verfahren zur untersuchung von wirkstoffen zur beeinflussung intrazellulärer vorgänge |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1264178A2 true EP1264178A2 (de) | 2002-12-11 |
Family
ID=7635682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01925461A Withdrawn EP1264178A2 (de) | 2000-03-17 | 2001-03-15 | Anordnung und verfahren zur untersuchung von wirkstoffen zur beeinflussung intrazellulärer vorgänge |
Country Status (4)
Country | Link |
---|---|
US (1) | US20040023228A1 (de) |
EP (1) | EP1264178A2 (de) |
DE (1) | DE10013854A1 (de) |
WO (1) | WO2001068680A2 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102014011441B4 (de) * | 2014-08-07 | 2020-03-19 | Autogyro Ag | Tragschrauber |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4301005A1 (de) * | 1993-01-18 | 1994-07-21 | Diagen Inst Molekularbio | Verfahren und Vorrichtung zur Bewertung der Fitness von Biopolymeren |
JP3517241B2 (ja) * | 1993-01-18 | 2004-04-12 | エボテック バイオシステムズ アクチェン ゲゼルシャフト | 生体高分子の適応度を評価するための方法および装置 |
DE19533092A1 (de) * | 1995-09-07 | 1997-03-13 | Basf Ag | Vorrichtung zur parallelisierten Zweiphotonen-Fluoreszenz-Korrelations-Spektroskopie (TPA-FCS) und deren Verwendung zum Wirkstoff-Screening |
WO1997021832A1 (de) * | 1995-12-08 | 1997-06-19 | Evotec Biosystems Gmbh | Verfahren zur bestimmung von nukleinsäuremolekülen in niedriger konzentration |
AU9541398A (en) * | 1997-09-19 | 1999-04-12 | Evotec Biosystems Gmbh | Method for measuring the association of substructures of pathological protein deposits |
DE19757740C2 (de) * | 1997-12-23 | 2000-04-13 | Evotec Biosystems Ag | Verfahren zum Nachweis von Assoziations-, Dissoziations-, Verknüpfungs- oder Spaltreaktionen sowie Konformationsänderungen mittels Koinzidenzanalyse |
US6872537B1 (en) * | 1998-04-14 | 2005-03-29 | Regents Of The University Of California | Assays for the detection of microtubule depolymerization inhibitors |
US6582907B1 (en) * | 1999-12-09 | 2003-06-24 | Pharmacia & Upjohn Company | Use of fluorescence correlation spectroscopy to identify compounds that bind to target species under isothermal denaturing conditions |
-
2000
- 2000-03-17 DE DE10013854A patent/DE10013854A1/de not_active Withdrawn
-
2001
- 2001-03-15 WO PCT/EP2001/002922 patent/WO2001068680A2/de not_active Application Discontinuation
- 2001-03-15 US US10/221,953 patent/US20040023228A1/en not_active Abandoned
- 2001-03-15 EP EP01925461A patent/EP1264178A2/de not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO0168680A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2001068680A2 (de) | 2001-09-20 |
DE10013854A1 (de) | 2001-09-20 |
WO2001068680A3 (de) | 2002-08-22 |
US20040023228A1 (en) | 2004-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60038127T2 (de) | Methoden und syteme zur überwachung intrazellulärer bindereaktionen | |
DE69329274T2 (de) | Hämatologisches Kontrollprodukt mit Leukozytenanalogen; und Methoden zu ihrer Herstellung und Anwendung | |
Keij et al. | Staining of mitochondrial membranes with 10‐nonyl acridine orange MitoFluor Green, and MitoTracker Green is affected by mitochondrial membrane potential altering drugs | |
DE69328772T2 (de) | Suspensionsmedien für hämatoligische zusammensetzungen und methode für ihren gebrauch | |
EP0679251B1 (de) | Verfahren und vorrichtung zur bewertung der fitness von biopolymeren | |
EP1248947B1 (de) | Verfahren und vorrichtung zur charakterisierung einer kulturflüssigkeit | |
DE69022819T2 (de) | Verbindungen und Reagenzien zur Bestimmung von Retikulozyten. | |
DE2953524A1 (de) | Biologisches messverfahren | |
DE69905291T2 (de) | Bioluminenztest für agonisten oder antagonisten eines kalzium-gekuppelten-rezeptors | |
EP0946855A1 (de) | Verfahren und vorrichtungen zur distanzmessung zwischen objektstrukturen | |
Augustine | Combining patch-clamp and optical methods in brain slices | |
EP3491364B1 (de) | Kombiniertes optisch-spektroskopisches verfahren zur bestimmung von mikrobiellen erregern | |
EP2167940B1 (de) | Verfahren zum bestimmen eines messwerts auf der basis von einzelmolekülereignissen | |
Patrizio et al. | Counting numbers of synaptic proteins: absolute quantification and single molecule imaging techniques | |
DE60214561T2 (de) | Fluorimetrische Multi-Parameter-Analyse in einer parallelen Multi-Fokus-Anordnung | |
DE60010323T2 (de) | Fluoreszenzkorrelationsspektroskopie zur identifizierung von verbindung-ziel-bindung | |
EP1264178A2 (de) | Anordnung und verfahren zur untersuchung von wirkstoffen zur beeinflussung intrazellulärer vorgänge | |
DE102008060991A1 (de) | Subtrate zur Selektion und spezifischen Beeinflussung der Funktion von Zellen | |
EP1024363A2 (de) | Quantitative Bestimmung von Analyten in einem heterogenen System | |
CH675485A5 (de) | ||
DE60301959T2 (de) | Verfahren zum nachweis von änderungen in morphologischen zellparametern | |
O’Malley et al. | Fluorescent calcium indicators: subcellular behavior and use in confocal imaging | |
Miyazaki et al. | Synapse-to-synapse variation of calcium channel subtype contributions in large mossy fiber terminals of mouse hippocampus | |
EP4056990A1 (de) | Verfahren und vorrichtung zur respirometrischen bestimmung der antibakteriellen wirksamkeit antibiotischer substanzen mittels auf lumineszenz basierender oxymetrie | |
DE102007010860B4 (de) | Verfahren zur Identifikation eines Partikels mit zwei oder mehr monodispers eingebetteten Fluorophoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020910 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
17Q | First examination report despatched |
Effective date: 20051121 |
|
17Q | First examination report despatched |
Effective date: 20051121 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20080320 |